This is India's most expensive stock, with share price of Rs 1.5 Lakh, not Mukesh Ambani's Reliance, Ratan Tata's TCS or Adani, but it is…
MRF Share Price: Earlier this year, on March 4, MRF's share had fallen close to Rs 1 lakh. After which, the stock has witnessed an upward rally in the past three months and delivered around 50% returns in that short span.
With a single share priced at over Rs 1.5 lakh, MRF is not a stock that fits into every investor's portfolio. Today, MRF Limited became the most expensive stock in the country as its share price crossed Rs 1.5 lakh. Over the past three months alone, the stock has delivered strong returns. MRF Share Price
On Wednesday, the MRF stock opened at Rs 1,44,945 and climbed to Rs 1,50,995 during trading hours and reached its all-time high of Rs 1,51,283.40, which it had reached in February 2024. After this surge, MRF once again surpassed Elcid Investments to become India's costliest stock.
The stock had dropped to around Rs 1 lakh on March 4 this year but again revived and gained nearly 50% in just three months. Over the last one year, MRF has delivered a return of around 14%, while its five-year returns are 132%. MRF Share Price Performance
The Rs 1.5 lakh mark had been a psychological barrier for the stock and it has now breached it. The company manufactures tyres for passenger cars, two-wheelers, trucks, and even Indian Air Force's Sukhoi-30 MKI fighter jets. It also produces toys under the 'Funskool' brand and has a presence in the paints segment as well.
In FY 2025, the company reported revenue of Rs 28,153 crore and a net profit of Rs 1,869 crore shows its strong financial performance.
Looking at the company's history, MRF's share was priced at around Rs 1,100 in 1995. Over the past 30 years, it has delivered a compounded annual growth rate (CAGR) of 18.5%. By 2005, the share price had risen to around Rs 3,500. During this period, the company expanded its production capacity and entered export markets, resulting in consistent revenue growth.
From 2005 to 2015, MRF capitalized on both domestic and global demand, expanding into truck, bus, and off-road tire segments. By 2015, the stock had crossed the Rs 40,000 level, representing a CAGR of 27.8%. During this time, the company also diversified into new areas like toys (Funskool) and paints, and developed specialized tyres for the Indian market.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
16 minutes ago
- Mint
Indian shares inch lower as Kotak earnings drag financials, trade deal delay weighs
By Bharath Rajeswaran and Vivek Kumar M (Reuters) -Indian shares inched lower on Monday as weak results from Kotak Mahindra Bank weighed on sentiment, while uncertainty over trade talks with the U.S. added to overall caution. The Nifty 50 fell 0.16% to 24,798.9 points and the BSE Sensex lost 0.2% to 81,325.4 as of 10:03 a.m. IST. The broader small-caps and mid-caps lost 0.3% and 0.2%, respectively. Negotiations between India and the United States remained deadlocked over tariff cuts on agriculture and dairy products, dimming hopes of an interim deal ahead of U.S. President Donald Trump's August 1 deadline. This is in contrast to a framework trade agreement struck between the U.S. and European Union over the weekend, easing fears of a bigger trade war between the two allies, which account for almost a third of global trade. High-weightage financials and private banks lost 0.2% and 1%, respectively, dragged by a 7% fall in Kotak Mahindra Bank after it posted a drop in quarterly profit. The IT index lost 0.5%, with Tata Consultancy Services shedding 1.6% after it announced plans to reduce its workforce by 2% in fiscal year 2026. The Nifty 50 and 30-stock Sensex have logged four consecutive weekly losses due to weak earnings, foreign outflows and uncertainty over the U.S.-India trade deal. "A dull earnings season and the lingering delay in the India-U.S. trade deal have clearly cast a shadow on market sentiment. With valuations still stretched across the board, investors are understandably treading with heightened caution," said G Chokkalingam, founder and head of research at Equinomics Research. Among individual stocks, Mphasis gained 2.4% on posting quarterly results in-line with estimates and on strong deal bookings, which has boosted the IT company's revenue growth outlook. SBI Cards and Payment Services lost 3.7% after missing profit estimates in the June quarter. (Reporting by Vivek Kumar M and Bharath Rajeswaran; Editing by Eileen Soreng and Mrigank Dhaniwala)
India.com
16 minutes ago
- India.com
Dhoni receives Rs 60000000, Abhishek Bachchan Rs 1900000 monthly from SBI due to..., Reason will amaze you!
State Bank of India (SBI) is the largest government-owned and leading bank in the country, serving over 50 crore customers, with more than 50,000 employees and over 22,500 branches. People usually visit banks to take loans or to deposit money to save or earn interest. But the country's biggest bank pays cricketer MS Dhoni Rs 6 crore and actor Abhishek Bachchan Rs 18.5 lakh every month. You might be wondering why the bank pays these large sums of money to these two personalities. Even though Mahendra Singh Dhoni no longer plays cricket, he still enjoys immense popularity. Dhoni is a brand endorsement juggernaut, having received a hefty part of his earnings from his brand endorsements. There is a long list of companies that are utilizing Dhoni's brand image, and one of them is SBI. Since 2023, Dhoni has been an ambassador for India's largest bank, State Bank of India, and has been appearing in advertisements for SBI. SBI pays a hefty amount of money for brand endorsement. For endorsing State Bank of India (SBI)'s schemes, plans, and various banking facilities through advertisements, MS Dhoni receives an annual fee of ₹6 crores. MS Dhoni is the brand image of SBI and receives this fee for that purpose. Sharing a post, SBI's official Instagram account wrote, 'We are pleased to onboard MS Dhoni as Brand Ambassador of SBI. Mr. Dhoni's association with SBI as a satisfied customer makes him a perfect embodiment of our brand's ethos. With this partnership, we aim to reinforce our commitment to serving the nation and our customers with trust, integrity and unwavering dedication. – Mr Dinesh Khara, Chairman SBI.' The post was published on October 28, 2023. SBI also pays Abhishek Bachchan Rs 18.9 lakh every month. This is the amount the Bachchan family receives as rent because Abhishek has let out the ground floor of his opulent Juhu bungalow, Ammu and Vats, to SBI. The lease is for 15 years, and according to the lease, SBI pays the Bachchan family Rs 18.9 lakh every single month as rent. In fact, according the the report published on Abhishek makes this amount without any effort. The property, located near the Bachchan family's residence 'Jalsa,' spans 3,150 square feet. Essentially, Abhishek Bachchan makes almost ₹19 lakh, just for a ground-floor flat rental. The lease agreement was registered on September 28, 2021. The lease agreement spans 15 years and includes scheduled rent hikes over time: After 5 years, the monthly rent will increase to Rs 23.6 lakh. After 10 years, it will further rise to Rs 29.5 lakh.
Economic Times
16 minutes ago
- Economic Times
Market in consolidation mode; triggers needed, says Sunil Subramaniam
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads "Another reason for pharma's past underperformance is that FIIs were driving the selling pressure. They closely track export-oriented sectors. So the recent post-results bounce in pharma is largely driven by DIIs. FIIs still haven't firmed up their stance on India. They remain a bit cautious, especially because the delay in the BTA (Bilateral Trade Agreement) hasn't helped sentiment," says Sunil Subramaniam , Market like you said, the question is—why were they under pressure in the first place? I'd call it the Trump effect. Mr. Trump has been talking a lot about imposing heavy pharma tariffs. He hasn't actually done anything yet, but every time he makes such statements, it creates nervousness—whether he's targeting CDMO players or generics, and how he plans to go about it. That uncertainty has impacted the pharma sector, putting it under when individual companies are reporting good numbers, the market has no choice but to buy into them—because at least those companies are indicating a positive outlook. Plus, some of them may not even be impacted by tariffs, creating a window of opportunity. Also, the pharma space includes domestic-oriented businesses like hospitals and diagnostics, which are unaffected by U.S. tariff issues. So overall, pharma remains a defensive reason for pharma's past underperformance is that FIIs were driving the selling pressure. They closely track export-oriented sectors. So the recent post-results bounce in pharma is largely driven by DIIs. FIIs still haven't firmed up their stance on India. They remain a bit cautious, especially because the delay in the BTA (Bilateral Trade Agreement) hasn't helped we need to understand the market's movement over the last three months. Post-March, FIIs were actually buyers in April and May, and even in June, though to a lesser extent. Meanwhile, if you look at the end of March, mutual fund DIIs—especially domestic mutual funds—had built up cash positions to around 7.25% of their April and May, both mutual funds and FIIs were buying, which supported the market. But starting this month, mutual fund cash levels are back down to around 5%, which is close to their lower limit. That means DIIs don't have as much cash left to deploy, apart from the fresh SIP looking at last earnings season and market levels, domestic funds have largely deployed their cash. FIIs, on the other hand, had expected some action around the BTA by July 9, which then got pushed to August 1. But now, even that deadline seems unlikely to be met. The Indian trade delegation has returned from the U.S. without a deal. Sticking points remain—like agriculture—and they won't be easy to the question now is whether Trump will extend the 10% tariff pause beyond August 1 or slap a 26% tariff on India and then negotiate, like he did with Japan—imposing higher tariffs first and then signing a deal at 19%. That kind of uncertainty around the India-U.S. BTA is keeping FIIs factor is China. While China and the U.S. haven't signed a full BTA either, they seem to have reached some understanding. Meanwhile, China's markets have been beaten down so much that the one-year forward P/E is around 11—compared to India's 22. And China's economy is about 4.5 times larger than India's. Even at 4% growth, those are big numbers. So FIIs are starting to see more value in China, pulling some attention away from as for your question on the next trigger—clearly, a breakthrough on the BTA front, like an interim deal or assurance that tariffs will be capped below 20%, could bring FIIs back. On the domestic side, it's the ongoing earnings season. Results have been mixed. The IT sector, for instance, didn't post terrible earnings, but weak guidance is weighing heavily, especially in the absence of FII DIIs have already used most of their cash, their incremental buying will depend on the inflow from SIPs and earnings results. So companies with strong earnings and forward guidance will likely get DII if the early festival season gives good signs on the consumption front, that could also be a positive trigger. Until then, expect the market to remain in a sideways, consolidative phase for some time.
